| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/02/2003 | EP1267933A2 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes |
| 01/02/2003 | EP1267932A1 Anti-infective active substance combinations and the use thereof for the topical treatment of fungus diseases of toe and finger nails |
| 01/02/2003 | EP1267931A1 Rhodamine derivatives for photodynamic diagnosis and treatment |
| 01/02/2003 | EP1267929A2 Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| 01/02/2003 | EP1267925A1 Treatment of fungal infection with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies |
| 01/02/2003 | EP1267913A2 Methods for administration of therapeutic agents on an antiangiogenic schedule |
| 01/02/2003 | EP1267904A2 Polypeptoid pulmonary surfactants |
| 01/02/2003 | EP1267903A1 Methods for treating glaucoma |
| 01/02/2003 | EP1267902A1 Cosmetic use of hop and ornithine |
| 01/02/2003 | EP1267901A1 Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress |
| 01/02/2003 | EP1267900A1 Emulsion containing a plant extract, method for producing said emulsion and for obtaining a plant extract |
| 01/02/2003 | EP1267898A2 Bile acid containing prodrugs with enhanced bioavailability |
| 01/02/2003 | EP1267897A1 Treatment of congestive heart failure by pretreated autologous blood |
| 01/02/2003 | EP1267896A1 Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death |
| 01/02/2003 | EP1267895A1 Use of feracryl for the treatment of peptic/duodenal ulcer and/or cholera |
| 01/02/2003 | EP1267894A2 Viscoelastics for use in middle ear surgery |
| 01/02/2003 | EP1267893A2 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections |
| 01/02/2003 | EP1267892A2 Use of cdp-choline for the treatment of alcohol withdrawal syndrome |
| 01/02/2003 | EP1267891A2 Antiadhesive carbohydrates |
| 01/02/2003 | EP1267890A2 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity |
| 01/02/2003 | EP1267889A1 Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
| 01/02/2003 | EP1267888A1 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 01/02/2003 | EP1267887A2 The use of cocoa procyanidins combined with acetylsalicyclic acid as an anti-platelet therapy |
| 01/02/2003 | EP1267886A2 Vitamin d compounds used to stabilize kidney transplants |
| 01/02/2003 | EP1267885A1 Male contraceptive formulation comprising norethisterone |
| 01/02/2003 | EP1267884A1 Compositions for use as penetration promoters in transdermal formulations for highly lipophilic active ingredients |
| 01/02/2003 | EP1267883A2 Bile secretion promoting composition containing a prostaglandin |
| 01/02/2003 | EP1267882A2 Apoptosis inhibitor with prostaglandin structure |
| 01/02/2003 | EP1267880A1 Low dose entecavir formulation and use |
| 01/02/2003 | EP1267879A2 Sustained release beadlets containing stavudine |
| 01/02/2003 | EP1267878A2 Compounds with 5-ht activity useful for controlling visual field loss |
| 01/02/2003 | EP1267877A1 Use of pyrido 3,2-e]-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction |
| 01/02/2003 | EP1267876A1 Thrombin inhibitors |
| 01/02/2003 | EP1267875A1 Sigma receptor ligands and their medical uses |
| 01/02/2003 | EP1267874A2 Therapeutic uses of ppar mediators |
| 01/02/2003 | EP1267873A2 A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer |
| 01/02/2003 | EP1267872A2 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 01/02/2003 | EP1267871A2 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| 01/02/2003 | EP1267870A2 Inhibition of cytokine generation |
| 01/02/2003 | EP1267869A1 Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance |
| 01/02/2003 | EP1267868A2 Inhibitors of melanocyte tyrosinase as topical skin lighteners |
| 01/02/2003 | EP1267867A1 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
| 01/02/2003 | EP1267866A2 The treatment of respiratory diseases |
| 01/02/2003 | EP1267865A2 Amiodarone-containing parenteral solution |
| 01/02/2003 | EP1267864A1 A synergistic anti-malarial formulation |
| 01/02/2003 | EP1267863A2 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents |
| 01/02/2003 | EP1267862A2 Methods and compositions for improving sleep |
| 01/02/2003 | EP1267861A2 Composition comprising paracetamol and niflumic acid |
| 01/02/2003 | EP1267860A1 Butylnitrone containing compositions for inhibition of cancer development |
| 01/02/2003 | EP1267859A2 Treatment of psoriasis |
| 01/02/2003 | EP1267858A2 Diphenyl ketoaldehyde derivatives with anti-hiv activity |
| 01/02/2003 | EP1267857A1 Method of inhibiting the expression of inflammatory cytokines and chemokines |
| 01/02/2003 | EP1267856A2 Treatment of icu-associated hypocalcemia with vitamin d compounds |
| 01/02/2003 | EP1267855A2 Vasopeptidase inhibitors to treat isolated systolic hypertension |
| 01/02/2003 | EP1267854A2 Highly selective inhibitors of the urokinase plasminogen activator |
| 01/02/2003 | EP1267853A2 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 01/02/2003 | EP1267852A2 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| 01/02/2003 | EP1267851A2 Method and compositions for preventing hormone induced adverse effects |
| 01/02/2003 | EP1267850A2 Compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus |
| 01/02/2003 | EP1267849A2 Restricting reinstatement of drug use |
| 01/02/2003 | EP1267848A1 Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer |
| 01/02/2003 | EP1267847A2 5ht 2 agonists for controlling iop and treating glaucoma |
| 01/02/2003 | EP1267846A1 Transdermal therapeutic system for the delivery of lerisetron |
| 01/02/2003 | EP1267843A1 System for transporting active substances in a biological system |
| 01/02/2003 | EP1267841A1 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine |
| 01/02/2003 | EP1267839A2 Microspheres for active embolization |
| 01/02/2003 | EP1267837A1 Matrices containing nitric oxide donors and reducing agents and their use |
| 01/02/2003 | EP1267836A1 Process for the preparation of accelerated release formulations using compressed fluids |
| 01/02/2003 | EP1267835A1 D and l etherlipid stereoisomers and liposomes |
| 01/02/2003 | EP1267834A1 Cationic liposomes |
| 01/02/2003 | EP1267833A1 Pharmaceutical preparations and their manufacture |
| 01/02/2003 | EP1267832A1 New self emulsifying drug delivery system |
| 01/02/2003 | EP1267831A1 New self emulsifying drug delivery system |
| 01/02/2003 | EP1267828A2 Pharmaceutical preparations |
| 01/02/2003 | EP1267827A2 Method for treating dry eye |
| 01/02/2003 | EP1267826A1 Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| 01/02/2003 | EP1267822A2 Use of 3,4-dihydroxy-mandelic acid for protecting against oxidative damage caused by ultra-violet light |
| 01/02/2003 | EP1267819A2 Preparation containing quinoxaline derivatives |
| 01/02/2003 | EP1267808A2 Compositions and methods for treating hair loss using oximyl- and hydroxylamino- prostaglandins |
| 01/02/2003 | EP1267807A2 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| 01/02/2003 | EP1267806A2 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| 01/02/2003 | EP1267803A2 Compositions and methods for treating hair loss using c 16? - c 20? aromatic tetrahydro prostaglandins |
| 01/02/2003 | EP1267800A1 Methods of modulating hair growth |
| 01/02/2003 | EP1267798A1 Treatment of skin damage using polyenylphosphatidylcholine |
| 01/02/2003 | EP1267765A1 Antibiotic and antifungal compositions |
| 01/02/2003 | EP1267760A2 Medical procedure |
| 01/02/2003 | EP1267642A1 Starch sub-types and lipid metabolism |
| 01/02/2003 | EP1267639A1 Carbohydrate system and a method for providing nutriton to a diabetic |
| 01/02/2003 | EP1267635A1 Supplementation of equine feedstuffs |
| 01/02/2003 | EP1267622A2 Anthelmintic combinations |
| 01/02/2003 | EP1219614A9 Benzene sulfonamides as PDE-V inhibitors for the use against erectile dysfunction |
| 01/02/2003 | EP1210944A4 Blood plasma replacement solution |
| 01/02/2003 | EP1139755A4 Method for treatment of bacterial infections with once or twice-weekly administered rifalazil |
| 01/02/2003 | EP1115716B1 2-phenylpyran-4-one derivatives |
| 01/02/2003 | EP1113798B1 Topical formulation of alkyl-, phenyl-pyridone |
| 01/02/2003 | EP1109785B1 Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation |
| 01/02/2003 | EP1105102B1 Pharmaceutical composition for injection based on a pharmaceutically acceptable clopidogrel or ticlopidin salt |
| 01/02/2003 | EP1083897A4 Hiv integrase inhibitors |
| 01/02/2003 | EP1073654A4 2,3-olefinic epothilone derivatives |
| 01/02/2003 | EP1073648A4 12,13-modified epothilone derivatives |